<DOC>
	<DOCNO>NCT00884273</DOCNO>
	<brief_summary>This Phase 3b clinical study prostate cancer patient aim compare current standard therapy gonadotrophin release hormone ( GnRH ) agonist , goserelin ( 3.6 mg ; plus anti-androgen flare protection , bicalutamide ) , novel GnRH antagonist , degarelix ( 240 mg start dose/80 mg maintenance dose ) respect mean percentage reduction prostate volume . The hypothesis degarelix could decrease prostate size least effectively combination GnRH agonist anti-androgen flare protection .</brief_summary>
	<brief_title>Investigation Effect Degarelix Terms Prostate Volume Reduction Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Patient give write informed consent 2 . Patient 18 year old 3 . Patient histologically confirm prostate cancer 4 . Patient serum prostatespecific antigen ( PSA ) level screen &gt; 2 ng/mL 5 . The prostate size &gt; 30 cubic centimetre ( cc ) , measure TRUS 6 . Patient bonescan within 12 week inclusion 7 . Patient must able undergo transrectal examination 8 . Patient estimate life expectancy least 12 month 1 . Any previous treatment prostate cancer 2 . Previous transurethral resection prostate ( TURP ) 3 . Is consider candidate medical castration 4 . Use urethral catheter 5 . Is currently treat 5alpha reductase inhibitor 6 . Is currently treat alphaadrenoceptor antagonist 7 . Treatment botulinum toxin A ( Botox ) 8 . Require radiotherapy trial 9 . History severe untreated asthma , anaphylactic reaction , severe urticaria and/or angioedema 10 . Hypersensitivity towards component investigational product excipients 11 . Previous history presence another malignancy 12 . A clinically significant disorder 13 . A corrected QT interval 450 msec 14 . Mental incapacity language barrier preclude adequate understanding cooperation 15 . Receipt investigational drug within last 28 day proceed screen 16 . Previous participation degarelix trial</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>